• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.

作者信息

Sato Shuku, Tamai Yotaro

机构信息

Division of Hematology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

出版信息

Int J Hematol. 2022 Mar;115(3):299-300. doi: 10.1007/s12185-022-03296-x. Epub 2022 Feb 8.

DOI:10.1007/s12185-022-03296-x
PMID:35133573
Abstract
摘要

相似文献

1
Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.阿扎胞苷和维奈克拉治疗后血液学缓解的具有组织细胞形态的急性单核细胞白血病
Int J Hematol. 2022 Mar;115(3):299-300. doi: 10.1007/s12185-022-03296-x. Epub 2022 Feb 8.
2
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
3
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
4
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.维奈克拉联合阿扎胞苷和供者淋巴细胞输注治疗异基因造血干细胞移植后复发的急性髓系白血病患者。
Ann Hematol. 2022 Jan;101(1):119-130. doi: 10.1007/s00277-021-04674-x. Epub 2021 Sep 27.
5
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.
6
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.将维奈克拉、阿扎胞苷与T细胞双特异性抗体联合用于治疗急性髓系白血病：一项临床前评估
Leukemia. 2024 Feb;38(2):398-402. doi: 10.1038/s41375-023-02127-0. Epub 2024 Jan 11.
7
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.维奈托克与阿扎胞苷用于不适宜接受强化化疗的中国初治急性髓系白血病患者
Signal Transduct Target Ther. 2023 May 3;8(1):176. doi: 10.1038/s41392-023-01394-8.
8
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.维奈托克联合阿扎胞苷作为晚期急性髓系白血病患者挽救治疗的疗效及预测因素：一项多中心回顾性研究
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
9
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
10
Azacitidine and Venetoclax in AML.阿扎胞苷与维奈克拉治疗急性髓系白血病
N Engl J Med. 2020 Nov 19;383(21):2088. doi: 10.1056/NEJMc2029153.

引用本文的文献

1
Acute monocytic leukaemia with histiocytic differentiation and erythrophagocytosis.伴有组织细胞分化及红细胞吞噬现象的急性单核细胞白血病。
Hematol Transfus Cell Ther. 2023 Oct-Dec;45(4):519-520. doi: 10.1016/j.htct.2022.11.007. Epub 2022 Dec 5.

本文引用的文献

1
Malignant histiocytosis in the leukaemic stage: a new entity (M5c-AML) in the FAB classification?白血病期恶性组织细胞增多症：FAB分类中的一种新实体（M5c型急性髓系白血病）？
Leukemia. 1994 Mar;8(3):502-6.
2
Leukemia after true histiocytic lymphoma: another type of acute monocytic leukemia with histiocytic differentiation (AML-M5c)?真性组织细胞淋巴瘤后发生的白血病：另一种具有组织细胞分化的急性单核细胞白血病（AML-M5c）？
Leukemia. 1995 Aug;9(8):1389-91.